Petros Pharmaceuticals, Inc. (PTPI) Stock Forecast
PTPI analyst forecast
as of October 21, 2026- Analyst consensus
- Buy 4.00 / 5 from 1 analysts
- Price target
- $1.00 average of analyst targets
- Upside to target
- +39,900.0% from the latest close
- Next earnings
- —
- 52-week range
- $0.00 – $0.02
PTPI analyst ratings
1 analystsNumber of analysts at each rating.
PTPI price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
PTPI earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; PTPI beat in 2 of 7.
What analysts expect from PTPI
1 analysts cover Petros Pharmaceuticals; their consensus rating is buy (4.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $1.00, 39,900.0% above the latest close of $0.00. Petros Pharmaceuticals beat the EPS estimate in 2 of the last 7 quarters.
Related: PTPI income statement, PTPI key metrics, PTPI chart. See the PTPI stock overview for the latest quote and news.
PTPI forecast FAQ
What is Petros Pharmaceuticals's price target?
The average analyst price target for Petros Pharmaceuticals is $1.00, 39,900.0% above the latest close of $0.00.
Is Petros Pharmaceuticals a buy, hold or sell?
Of 1 analysts covering Petros Pharmaceuticals, 0 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
Does Petros Pharmaceuticals usually beat earnings estimates?
Petros Pharmaceuticals reported EPS at or above the analyst estimate in 2 of the last 7 quarters.